The final patient completes Phase I trial enrollment, evaluating safety and tolerability for Biomica s microbiome-based immuno-oncology drug, BMC128
REHOVOT, Israel, Jan. 17, 2024 /PRNewswire/ .
Evogene Ltd. (NASDAQ:EVGN) Q3 2023 Earnings Call Transcript November 15, 2023 Operator: Ladies and gentlemen, thank you for standing by. Welcome to Evogene’s Third Quarter 2023 Results Conference Call. All participants are present in listen-only mode. Following management’s formal presentation, instructions will be given for the question-and-answer session. [Operator Instructions] As a reminder, this conference […]
Biomica Announces First Patient Dosed in its Phase I Study of its Microbiome-Based Immuno-Oncology Drug streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Biomica Announces Successful Enrollment of First Patient in its Phase I Study of Microbiome-Based Immuno-Oncology Drug streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.